New drug targets 'Undruggable' KRAS cancer mutations in major trial
NCT ID NCT07148128
Summary
This early-stage clinical trial is testing a new drug called WEF-001 in people with advanced cancers that have a specific KRAS gene mutation. The study aims to find a safe dose and see if the drug can shrink tumors in cancers like pancreatic, colorectal, and lung cancer that have stopped responding to standard treatments. About 110 participants will receive the drug to monitor for side effects and early signs of effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology Dallas
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
Contact
-
Next Oncology, San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
Contact
-
Oxford University Hospital
RECRUITINGHeadington, Oxford, 0X3 9DU, United Kingdom
Contact
Contact
Contact
-
Princess Margareth Cancer Center
RECRUITINGToronto, Ontario, Canada
Contact
Conditions
Explore the condition pages connected to this study.